

Delivering original and innovative new drugs as a Global Specialty Pharma

Capital to be Input (FY2022)

Financial capital
A strong financial base that supports sustained drug discovery

- Total capital: **¥747.8 billion**
- Ratio of equity attributable to owners of the parent company: **84.1%**

Manufacturing capital
A manufacturing base that ensures stable supply of high-quality pharmaceutical products

- Capital investment: **¥7.7 billion**
- Manufacturing centers: **2**

Intellectual capital
R&D abilities based on ONO's unique drug discovery approach and open innovation

- R&D costs: **¥95.3 billion**
- R&D cost-to-revenue ratio: **21.3%**

Human capital
Providing a challenger culture and opportunities for personal growth


- Number of employees (consolidated): **3,761**
- Annual training hours per employee: **54.8 hours**

Social capital
Various forms of partnership to create sustainable society

- Number of research collaborations with universities, biopharmaceutical companies, etc. More than **300** (Japan and overseas)

Natural capital
ECO VISION 2050 and environmental management

- Energy consumption: **86,067 MWh**
- Water resource consumption (water intake): **196.4 thousand m³**



Main products

- OPDIVO Intravenous Infusion**
Cancer
¥142.3 billion
- FORXIGA Tablets**
Diabetes-Heart Failure-CKD
¥56.5 billion
- ORENCIA for Subcutaneous Injection**
Rheumatoid arthritis
¥24.8 billion
- GLACTIV Tablets**
Type 2 Diabetes
¥22.5 billion
- KYPROLIS for Intravenous Injection**
Refractory multiple myeloma
¥8.7 billion
- PARSABIV Intravenous Infusion for Dialysis**
Secondary hyperparathyroidism
¥8.4 billion
- VELEXBRU Tablets**
Primary central nervous system lymphoma
Waldenström macroglobulinemia and lymphoplasmacytic lymphoma
¥8.5 billion
- ONGENTYS Tablets**
Parkinson's disease
¥5.0 billion

FY2022 results

- Economic Value**
- Stable income
 - Revenue: **447.2 billion yen**
 - Dividend per share: **70 yen** (payout ratio: 30.3%)
- Societal Value**
- Creation and provision of innovative drugs
 - Number of patients to whom our new drugs are delivered: about **850,000**
 - Number of approvals received: Japan, **4**; Korea, **4**; Taiwan **7**
 - Training diverse talent
 - Versatile human resources who support the management foundation: total **542**
- Environmental Value**
- Contributions to decarbonized society
 - Reduced greenhouse gas emissions **38.2%** (scope 1 and 2, compared to FY2017)
 - Contributions to water-recycling society
 - Water consumption: reduced **10.5%** (year on year)
 - See Materiality and KPI p. 27 for other indicators.

Relevant SDGs

